Compare ERII & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ERII | ANL |
|---|---|---|
| Founded | 1992 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 595.9M | 703.3M |
| IPO Year | 2008 | 2022 |
| Metric | ERII | ANL |
|---|---|---|
| Price | $9.39 | $13.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $17.07 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 721.9K | 652.4K |
| Earning Date | 05-06-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 5.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $134,987,000.00 | N/A |
| Revenue This Year | N/A | $36.02 |
| Revenue Next Year | $20.55 | N/A |
| P/E Ratio | $27.71 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.35 | $0.88 |
| 52 Week High | $18.31 | $17.25 |
| Indicator | ERII | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 34.85 | 53.54 |
| Support Level | N/A | $1.36 |
| Resistance Level | $11.54 | $17.25 |
| Average True Range (ATR) | 0.49 | 1.73 |
| MACD | -0.04 | -0.28 |
| Stochastic Oscillator | 3.51 | 42.26 |
Energy Recovery Inc designs and manufactures energy-saving technologies. The firm uses its proprietary pressure exchanger technology to help customers in multiple industries improve their operations and lower their emissions. Using its proprietary technology, it offers energy recovery devices, including pressure exchangers, pumps, and turbochargers, mainly used for seawater desalination and wastewater treatment. Additionally, the company is involved in the development of emerging technologies, such as the PX G1300 used in industrial and commercial refrigeration applications. The firm's reportable operating segments are: Water, which generates maximum revenue, and Emerging Technologies. Geographically, it generates maximum revenue from the Middle East, and the rest from other markets.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.